EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation

EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation
The European Commission has approved Novartis's Piqray (alpelisib) in combination with Faslodex (fulvestrant) for the treatment of advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) and harbors a PIK3CA mutation. The approval, which follows a recent positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use, covers men and postmenopausal women who have experienced disease progression following endocrine therapy as a singular therapy. "Piqray is an important new therapy for HR+/HER2- advanced breast cancer patients whose tumors have a PIK3CA mutation, and we look forward to making it available in countries across Europe," Kees Roks, head region Europe at Novartis Oncology, said in a
Subscribe or to access all post and page content.